Laura Kleiman, PhD, is the Founder and CEO of Reboot Rx, a nonprofit accelerating the development of affordable cancer treatments by repurposing generic drugs using their proprietary AI technology. The Reboot Rx team—composed of experts in oncology drug development, AI, and healthcare policy—is redefining the standard of care for patients who need effective and accessible treatments now.
Reboot Rx’s groundbreaking work has attracted support from leading philanthropists, recognition through awards such as the Massachusetts Next Generation Initiative and Extraordinary Women Advancing Healthcare, and features in Forbes, The Boston Globe, Inside Philanthropy, and more. Laura is a Draper Richards Kaplan Foundation Entrepreneur and a Henri Termeer Fellow.
Prior to founding Reboot Rx, Laura was a Scientific Research Director at the Dana-Farber Cancer Institute. She earned a PhD in Computational and Systems Biology from MIT and completed an American Cancer Society Postdoctoral Fellowship at the Massachusetts General Hospital and Harvard Medical School.
